Tendering and biosimilars: what role for value-added services?
Background: Access to biologic medicines (including biosimilars) across Europe is largely governed by a process of tendering conducted by health authorities. Over-reliance on treatment costs in awarding tenders has the potential to hinder competition and undermine the long-term sustainability of bio...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
Taylor & Francis Group,
2020-01-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!